Journal
NEUROLOGY
Volume 76, Issue 8, Pages S20-S27Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e31820db341
Keywords
-
Categories
Funding
- Novartis Pharma AG
- Swiss Multiple Sclerosis Society
- Teva
- Merck-Serono
- Novartis
- Actelion
- Biogen-Idec
- GSK
- Sanofi-Aventis
- Advancell
- Allozyne
- BaroFold
- Bayer Health Care Pharmaceuticals
- Bayer Schering Pharma
- Bayhill Therapeutics
- BioMarin
- CLC Behring
- Elan
- Genmab
- Genmark
- GeNeuro SA
- GlaxoSmithKline
- Lilly
- MediciNova
- Novo Nordisk
- Peptimmune
- Santhera
- Roche
- UCB
- Wyeth
- Bayer
- Berlex
- BioMS
- Diogenix
- Eli-Lilly
- Genentech
- Guthy-Jackson/GGF
- Ono
- Teva Neuroscience
- Multiple Sclerosis Society of Canada
- Canadian Institutes of Health Research
Ask authors/readers for more resources
The oral sphingosine 1-phosphate (S1P) receptor (S1PR) modulator fingolimod has been shown to be effective in the treatment of patients with relapsing multiple sclerosis (MS). The drug binds with high affinity to 4 of the 5 G-protein-coupled S1P receptors (S1P(1-5)). After binding, the receptors are internalized, degraded, and thus functionally antagonized by fingolimod. Under physiologic conditions, S1P(1) mediates the egress of lymphocytes from secondary lymphoid organs to the peripheral circulation. Functional antagonism of S1P(1) by fingolimod results in a reduction in peripheral lymphocyte counts by inhibiting egress of lymphocytes, including potentially encephalitogenic T cells and their naive progenitors that would otherwise be present within the circulation. Despite the fingolimod-mediated reduction of lymphocyte counts, fingolimod-treated patients with MS have been shown to have few infections and related complications and were able to mount antigen-specific immune responses in vaccination studies. NEUROLOGY 2011;76 (Suppl 3):S20-S27
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available